Menopause Raises Hidden Heart Risks—Why Women Must Act Now
Menopause Raises Hidden Heart Risks—Why Women Must Act Now
Menopause Raises Hidden Heart Risks—Why Women Must Act Now
Menopause brings major changes to a woman's body, but one risk often goes unnoticed. After this life stage, heart disease and heart failure become a growing threat. Experts now stress the need for better awareness and prevention.
Dr. Priya Freaney, a cardiologist and assistant professor at Northwestern University, warns that many women underestimate the impact of menopause on heart health. She points out that hormonal shifts during this period can raise the risk of cardiovascular problems over time.
While modern medicine offers more treatment options than ever, Freaney highlights the importance of tailored care. Each patient's situation differs, so prevention strategies must adapt to individual needs. Her advice focuses on early action to protect heart function before complications arise.
The link between menopause and long-term heart risks remains a key concern for specialists. Freaney's recommendations centre on proactive measures to maintain cardiovascular health. Without proper attention, women face higher chances of heart disease in later years.
Garlic, Vitamin C, and Chlorophyll Team Up for Heart Health Breakthrough
Could a simple blend of garlic, vitamin C, and chlorophyll be the key to a healthier heart? New findings reveal surprising benefits for blood pressure and beyond.
Chuck Norris, 86, hospitalized after medical emergency in Hawaii
From Walker, Texas Ranger to recent films, Norris never slowed down—until now. Fans worldwide await news after his sudden hospitalization.
Blood Test Breakthrough Could Detect Hidden Artery Disease Years Earlier
A simple blood test could soon reveal invisible plaque buildup—long before it triggers a deadly event. Machine learning cracked the code in 45,000 patients' data.
Eli Lilly's retatrutide shows groundbreaking results in Type 2 diabetes trial
A triple-hormone drug could redefine diabetes care. Early data shows retatrutide outperforms competitors—but will regulators agree?